CO6660443A2 - Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg) - Google Patents

Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg)

Info

Publication number
CO6660443A2
CO6660443A2 CO12216949A CO12216949A CO6660443A2 CO 6660443 A2 CO6660443 A2 CO 6660443A2 CO 12216949 A CO12216949 A CO 12216949A CO 12216949 A CO12216949 A CO 12216949A CO 6660443 A2 CO6660443 A2 CO 6660443A2
Authority
CO
Colombia
Prior art keywords
peg
polyethylene glycol
factor viii
blood coagulation
conjugated factor
Prior art date
Application number
CO12216949A
Other languages
English (en)
Inventor
Henry William
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6660443(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of CO6660443A2 publication Critical patent/CO6660443A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un polímero biocompatible conjugado a FVIII por medio de uno o más residuos de cisteína, adecuadamente por medio de un enlazador a través de un enlace disulfuro reducido en FVIII, y composiciones farmacéuticas que comprenden esas formas conjugadas de FVIII.
CO12216949A 2010-04-30 2012-11-29 Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg) CO6660443A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII

Publications (1)

Publication Number Publication Date
CO6660443A2 true CO6660443A2 (es) 2013-04-30

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12216949A CO6660443A2 (es) 2010-04-30 2012-11-29 Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg)

Country Status (26)

Country Link
US (1) US20130150302A1 (es)
EP (1) EP2563402A1 (es)
JP (1) JP5870088B2 (es)
KR (1) KR20130055619A (es)
CN (1) CN102939108A (es)
AP (1) AP2012006575A0 (es)
AU (1) AU2011247147B2 (es)
BR (1) BR112012027590A2 (es)
CA (1) CA2797058A1 (es)
CL (1) CL2012003039A1 (es)
CO (1) CO6660443A2 (es)
CR (1) CR20120579A (es)
EA (1) EA201290938A1 (es)
EC (1) ECSP12012314A (es)
GB (2) GB201007357D0 (es)
HK (1) HK1173946A1 (es)
IL (1) IL222566A (es)
MX (1) MX2012012683A (es)
MY (1) MY160922A (es)
NI (1) NI201200160A (es)
NZ (1) NZ603939A (es)
PE (1) PE20130254A1 (es)
RU (1) RU2012144555A (es)
SG (1) SG184906A1 (es)
WO (1) WO2011135307A1 (es)
ZA (1) ZA201208989B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637007B2 (en) 2006-12-15 2014-01-28 Baxter International Inc. Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
CA2769326A1 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
ES2856055T3 (es) 2009-07-27 2021-09-27 Baxalta GmbH Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2590679T3 (es) 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR102025442B1 (ko) 2010-12-22 2019-09-25 박스알타 인코퍼레이티드 단백질에 수용성 지방산 유도체를 접합하기 위한 물질 및 방법
WO2013156488A2 (en) * 2012-04-16 2013-10-24 Leverton Licence Holdings Limited Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2788505C (en) * 2003-02-26 2018-09-04 Nektar Therapeutics Polymer-factor viii moiety conjugates
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
SI3130601T1 (sl) * 2004-11-12 2020-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
WO2006071801A2 (en) * 2004-12-27 2006-07-06 Baxter International Inc Polymer-von willebrand factor-conjugates
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
EP2209494B1 (en) 2007-10-09 2016-07-20 Polytherics Limited Novel conjugated proteins and peptides
WO2009130602A2 (en) 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
EP2326349B1 (en) 2008-07-21 2015-02-25 Polytherics Limited Novel reagents and method for conjugating biological molecules
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
PE20130254A1 (es) 2013-03-16
GB2492935B8 (en) 2014-10-29
GB201007357D0 (en) 2010-06-16
GB2492935B (en) 2014-04-30
AU2011247147B2 (en) 2014-09-18
IL222566A0 (en) 2012-12-31
WO2011135307A1 (en) 2011-11-03
JP5870088B2 (ja) 2016-02-24
US20130150302A1 (en) 2013-06-13
NI201200160A (es) 2013-04-19
GB201220667D0 (en) 2013-01-02
ECSP12012314A (es) 2013-05-31
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
ZA201208989B (en) 2014-02-26
GB2492935A (en) 2013-01-16
MY160922A (en) 2017-03-31
MX2012012683A (es) 2013-04-03
KR20130055619A (ko) 2013-05-28
NZ603939A (en) 2013-08-30
HK1173946A1 (en) 2013-05-31
EP2563402A1 (en) 2013-03-06
SG184906A1 (en) 2012-11-29
CA2797058A1 (en) 2011-11-03
GB2492935A8 (en) 2014-10-29
CR20120579A (es) 2013-04-25
IL222566A (en) 2017-12-31
CL2012003039A1 (es) 2014-01-24
AP2012006575A0 (en) 2012-12-31
RU2012144555A (ru) 2014-06-10
JP2013525414A (ja) 2013-06-20
CN102939108A (zh) 2013-02-20
BR112012027590A2 (pt) 2016-08-09

Similar Documents

Publication Publication Date Title
CO6660443A2 (es) Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg)
ECSP12012315A (es) FACTOR VIIa CONJUGADO PARA COAGULACIÓN DE LA SANGRE
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
MX362432B (es) Variantes de oxm pegilada.
CR20150386A (es) Composiciones de nanoparticulas de albumina y paclitaxel
GT201200339A (es) Compuestos, composiciones de tioacetato y mètodos de uso
UY37922A (es) Composiciones farmacéuticas que comprenden un profármaco deadrenomedulina basado en polietilenglicol
CL2021001142A1 (es) Nuevos conjugados citostáticos con ligandos de integrina
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
CU20130128A7 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
CY1125157T1 (el) Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση
CY1115734T1 (el) Συνθεσεις benzenesulfonamide, μεθοδος συνθεσης τους, και χρηση αυτων στην ιατρικη
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
AR081928A1 (es) Composicion de inmunoglobulinas humanas estabilizada
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
CY1115266T1 (el) Φαρμακευτικες συνθεσεις αερολυματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
CL2011002893A1 (es) Peptido derivado del factor viii; composicion que lo comprende; uso para aumentar la tolerancia a factor viii en individuos que padecen o estan en riesgo de padecer hemofilia a o hemofilia adquirida.
CL2009001083A1 (es) Variantes de receptores de la proteina c3 de complemento (crig), molecula quimerica y composicion farmaceutica que las comprende; uso de las variantes para preparar un medicamento para prevenir o tratar una enfermedad asociada al complemento, tal como una enfermedad inflamatoria o autoinmune.
ATE529096T1 (de) Pharmazeutische zusammensetzungen mit bradykinin- antagonisten und hyaluronsäure sowie anwendungen davon
UA109646C2 (uk) Терапевтичне застосування кон'югатів білка з полімером
TR200806305A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik bileşim